1669.9000 30.30 (1.85%)
NSE Jun 13, 2025 15:31 PM
Volume: 937.7K
 

1669.90
1.85%
ICICI Securities Limited
Traction in Ryaltris across EU and RoW markets drove a robust 22.5% YoY growth in Glenmark’s revenue in Q1FY24. Divestment of Razel and other derma brands took a toll on India growth (up 2.8% YoY).
Glenmark Pharmaceuticals Ltd. has gained 20.86% in the last 1 Month
More from Glenmark Pharmaceuticals Ltd.
Recommended